About Paraneoplastic antigen Ma3
Paraneoplastic antigen Ma3 (PNMA3) is a protein
from Homo sapiens identified by UniProt accession
Q9UL41, 463 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Paraneoplastic antigen Ma3 |
|---|
| UniProt accession | Q9UL41 |
|---|
| Gene | PNMA3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 463 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (35)
Diseases linked to this target (Open Targets).
- infect · score 0.07
- infection · score 0.07
- hypouricemia, renal, 2 · score 0.04
- glioblastoma multiforme · score 0.03
- melanoma · score 0.03
- Splenomegaly · score 0.02
- mitochondrial disease · score 0.02
- astrocytoma · score 0.02
- neoplasm · score 0.02
- coinfection · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UL41-F1 | alphafold | PREDICTED | 74.81 | — |
Amino-acid sequence (463 residues)
MPLTLLQDWC RGEHLNTRRC MLILGIPEDC GEDEFEETLQ EACRHLGRYR VIGRMFRREE NAQAILLELA QDIDYALLPR EIPGKGGPWE VIVKPRNSDG EFLNRLNRFL EEERRTVSDM NRVLGSDTNC SAPRVTISPE FWTWAQTLGA AVQPLLEQML YRELRVFSGN TISIPGALAF DAWLEHTTEM LQMWQVPEGE KRRRLMECLR GPALQVVSGL RASNASITVE ECLAALQQVF GPVESHKIAQ VKLCKAYQEA GEKVSSFVLR LEPLLQRAVE NNVVSRRNVN QTRLKRVLSG ATLPDKLRDK LKLMKQRRKP PGFLALVKLL REEEEWEATL GPDRESLEGL EVAPRPPARI TGVGAVPLPA SGNSFDARPS QGYRRRRGRG QHRRGGVARA GSRGSRKRKR HTFCYSCGED GHIRVQCINP SNLLLVKQKK QAAVESGNGN WAWDKSHPKS KAK
Explore Paraneoplastic antigen Ma3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets